Guidance may pressure states that bar treatment in public hospitals

Australia’s National Health and Medical Research Council released interim national clinical practice guidelines on Monday advising the conditional use of puberty suppressants in the care of trans and gender-diverse people aged under 18, after a year-long review of international evidence.

The advice comes from the commonwealth-funded NHMRC, which describes itself as one of the world’s largest medical research organisations, and it was developed after the federal government last year commissioned the council to respond to bans imposed by the Queensland and Northern Territory governments on treatment in public hospitals.

The interim guidelines could put pressure on state and territory governments to consider their positions on the treatment. The New Zealand government later followed suit — a move that was reported at the time to have drawn widespread opposition in the health sector and warnings that the bans would harm children.

The NHMRC explicitly rejected alternative approaches to gender-affirming care put forward by opponents of the approach, including the “wait and see” model, treating them as a form of withholding care for children that it said “can affect the young person’s physical and mental health, wellbeing, and ability to function.”

The guidelines do not require a child be distressed to be treated for gender incongruence, and they say a multi-disciplinary team “should be determined on a case-by-case basis.” Doctors should “prioritise the best interest and wellbeing of the young person and provide care that respects their autonomy,” the advice reads.

The guidance defines gender incongruence as the clinical term for a difference between a person’s gender and their sex recorded at birth. “It is not a mental health disorder,” it states, adding: “Some young people with gender incongruence will also experience significant distress, known as gender dysphoria.”

Puberty blockers are a class of drugs used to stop the body producing oestrogen and testosterone. Hormone replacement therapy replaces hormones produced in the body with synthetic hormones for the treatment of ailments like hormonal cancers, such as breast and prostate cancer, endometriosis and gender incongruence. Both treatments are common, covered by the Pharmaceutical Benefits Scheme for cisgender patients, and have been used for decades.

Puberty blockers have been used to treat children for a variety of conditions, such as precocious puberty, since the 1970s, and in gender-affirming care since the 1990s. The NHMRC advice largely aligns with the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, Australia’s only existing guidelines for doctors.

The NHMRC is an independent statutory agency funded by the commonwealth. Its interim advice on puberty blocking drugs is based on advice from its multidisciplinary gender guideline development committee and is “supported by a systematic review of the evidence,” the review said.

The review said: “Trans and gender-diverse young people experience unjust and avoidable health disparities arising from stigma, discrimination, and barriers to accessing health care.”

Public consultation on the interim advice, called “Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18”, is open until 18 January. The full guidelines will address other aspects of care, including the use of gender-affirming hormones, and are expected to be available in 2028.